A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.

Autor: Kurbatova EV; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Phillips PPJ; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California., Dorman SE; Medical University of South Carolina, Charleston, South Carolina., Sizemore EE; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Bryant KE; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Purfield AE; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.; United States Public Health Service Commissioned Corps, Rockville, Maryland., Ricaldi J; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Brown NE; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Johnson JL; Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio.; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda., Wallis CL; Lancet Laboratories and Bio Analytical Research Corporation South Africa (BARC SA), Johannesburg, South Africa., Akol JP; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda., Ocheretina O; GHESKIO, Port-au-Prince, Haiti., Van Hung N; Vietnam National Tuberculosis Program/National Lung Hospital, Hanoi, Vietnam., Mayanja-Kizza H; Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda., Lourens M; TASK, Cape Town, South Africa., Dawson R; Division of Pulmonology, Department of Medicine, University of Cape Town and University of Cape Town Lung Institute, Cape Town, South Africa., Nhung NV; Vietnam National Tuberculosis Program/National Lung Hospital, Hanoi, Vietnam., Pierre S; GHESKIO, Port-au-Prince, Haiti., Musodza Y; University of Zimbabwe College of Health Sciences, Harare, Zimbabwe., Shenje J; South African Tuberculosis Vaccine Initiative, Cape Town, South Africa., Badal-Faesen S; Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Vilbrun SC; GHESKIO, Port-au-Prince, Haiti., Waja Z; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Peddareddy L; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Scott NA; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Yuan Y; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Goldberg SV; U.S. Centers for Disease Control and Prevention, Atlanta, Georgia., Swindells S; University of Nebraska Medical Center, Omaha, Nebraska; and., Chaisson RE; Johns Hopkins University School of Medicine, Baltimore, Maryland., Nahid P; UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, California.

Publikováno v: American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2023 May 15; Vol. 207 (10), pp. 1376-1382.

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

Autor: Kityo, C, Szubert, AJ, Siika, A, Heyderman, R, Bwakura-Dangarembizi, M, Lugemwa, A, Mwaringa, S, Griffiths, A, Nkanya, I, Kabahenda, S, Wachira, S, Musoro, G, Rajapakse, C, Etyang, T, Abach, J, Spyer, MJ, Wavamunno, P, Nyondo-Mipando, L, Chidziva, E, Nathoo, K, Klein, N, Hakim, J, Gibb, DM, Walker, AS, Pett, SL, Mugyenyi, P, Musiime, V, Nambi, E, Ocitti, P, Ndigendawani, M, Kemigisa, M, Acen, J, Olebo, D, Mpamize, G, Amone, A, Okweny, D, Mbonye, A, Nambaziira, F, Rweyora, A, Kangah, M, Kabaswahili, V, Abongomera, G, Omongin, J, Aciro, I, Philliam, A, Arach, B, Ocung, E, Amone, G, Miles, P, Adong, C, Tumsuiime, C, Kidega, P, Otto, B, Apio, F, Baleeta, K, Mukuye, A, Abwola, M, Ssennono, F, Baliruno, D, Tuhirwe, S, Namisi, R, Kigongo, F, Kikyonkyo, D, Mushahara, F, Tusiime, J, Musiime, A, Nankya, A, Atwongyeire, D, Sirikye, S, Mula, S, Noowe, N, Kasozi, M, Mwebe, S, Atwine, L, Senkindu, T, Natuhurira, T, Katemba, C, Ninsiima, E, Acaku, M, Kyomuhangi, J, Ankunda, R, Tukwasibwe, D, Ayesiga, L, Reid, A, Mhute, T, Tinago, GC, Bhiri, J, Mudzingwa, S, Phiri, M, Steamer, J, Nhema, R, Warambwa, C, Mutsai, S, Nemasango, B, Moyo, C, Chitongo, S, Rashirai, K, Vhembo, S, Mlambo, B, Nkomani, S, Ndemera, B, Willard, M, Berejena, C, Musodza, Y, Matiza, P, Mudenge, B, Guti, V, Etyang, A, Agutu, C, Berkley, J, Maitland, K, Njuguna, P, Awuondo, K, Wale, S, Shangala, J, Kithunga, J, Mwarumba, S, Maitha, SS, Mutai, R, Lewa, ML, Mwambingu, G, Mwanzu, A, Kalama, C, Latham, H, Shikuku, J, Fondo, A, Njogu, A, Khadenge, C, Mwakisha, B, Wools-Kaloustian, K, Nyandiko, W, Cheruiyot, P, Sudoi, A, Meli, B, Karoney, M, Nzioka, A, Tanui, M, Mokaya, M, Ekiru, W, Mboya, C, Mwimali, D, Mengich, C, Choge, J, Injera, W, Njenga, K, Cherutich, S, Orido, MA, Lwande, GO, Rutto, P, Mudogo, A, Kutto, I, Shali, A, Jaika, L, Jerotich, H, Pierre, M, Mallewa, J, Kaunda, S, Van Oosterhout, J, O'Hare, B, Heydermann, R, Gonzalez, C, Dzabala, N, Kelly, C, Denis, B, Selemani, G, Mipando, LN, Chirwa, E, Banda, P, Mvula, L, Msuku, H, Ziwoya, M, Manda, Y, Nicholas, S, Masesa, C, Mwalukomo, T, Makhaza, L, Sheha, I, Bwanali, J, Limbuni, M

Background In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::76c8634db5b063d7f9a222c5f8130b9d
http://hdl.handle.net/10044/1/90457

Abstracts from HIVR4P 2024, the 5th HIV Research for Prevention Conference, 6 – 10 October, Lima, Peru & Virtual.

Publikováno v: Journal of the International AIDS Society. Oct2024 Supplement 1, Vol. 27, p1-92. 92p.